CMH Wealth Management LLC Buys 552 Shares of Eli Lilly and Company (NYSE:LLY)

CMH Wealth Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 4.1% during the 4th quarter, HoldingsChannel reports. The fund owned 13,872 shares of the company’s stock after purchasing an additional 552 shares during the quarter. Eli Lilly and Company comprises 2.5% of CMH Wealth Management LLC’s holdings, making the stock its 11th biggest position. CMH Wealth Management LLC’s holdings in Eli Lilly and Company were worth $10,709,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Wealthquest Corp lifted its position in Eli Lilly and Company by 0.4% in the 4th quarter. Wealthquest Corp now owns 5,278 shares of the company’s stock valued at $4,075,000 after acquiring an additional 22 shares in the last quarter. Amplius Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 4.2% during the fourth quarter. Amplius Wealth Advisors LLC now owns 1,526 shares of the company’s stock valued at $1,178,000 after purchasing an additional 61 shares in the last quarter. Harbor Investment Advisory LLC boosted its position in shares of Eli Lilly and Company by 5.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 10,696 shares of the company’s stock valued at $8,257,000 after buying an additional 546 shares during the last quarter. Gemmer Asset Management LLC increased its holdings in Eli Lilly and Company by 4.9% in the 4th quarter. Gemmer Asset Management LLC now owns 1,091 shares of the company’s stock worth $843,000 after buying an additional 51 shares in the last quarter. Finally, Overbrook Management Corp purchased a new position in Eli Lilly and Company in the 4th quarter worth about $7,321,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.2 %

Shares of LLY stock opened at $741.98 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a fifty day simple moving average of $779.00 and a two-hundred day simple moving average of $852.83. The firm has a market capitalization of $704.38 billion, a PE ratio of 80.21, a PEG ratio of 1.52 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $614.82 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 12.98 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Finally, Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.